Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection. Gane, E., Sulkowski, M., Ma, X., Nguyen, T., Hann, H., Hassanein, T., Elkhashab, M., Chan, S., Nahass, R., Bennett, M., Park, J., Jacobson, I., Bonacini, M., Ma, J., Yan, R., Knox, S. J., Stamm, L., Ramji, A., Han, S. B., Ayoub, W., Ravendhran, N., Kwo, P., Dieterich, D., Bae, H., Schiff, E. R., Lalezari, J., Fung, S., Yuen, M. ELSEVIER. 2021: S736

View details for Web of Science ID 000667753802065